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Background: Transcatheter aortic valve implantation (TAVI) is an alternative treatment
for high-risk patients with aortic valve disease. The JenaValve™, a second-generation
TAVI-device, has recently received CE-approval for transapical implantation (TA-
TAVI). Herein, we present early single-center clinical data of the initial 27 patients after
TA-TAVI with the JenaValve™.
Methods: Between January 2011 and Mai 2012, 27 patients (age 80.97.1, 19 female,
EuroScore 33.212.2%,) underwent TAVI with the JenaValve™. The primary endpoint
was all-cause mortality at 30 days, secondary endpoints included procedural success and
major adverse cardiac and cerebrovascular events. Echocardiographic valve function was
evaluated on ambulantory visits at least once within the first 3 month after valve
implantation.
Results: TA-TAVI was successfully performed in all patients with a mean radiation time
of 11.48.4min. The average implanted device sizes included 23mm (n8), 25mm
(n12) and 27mm (n7), redilatation after deployment was necessary in 15/27 (55.6%).
Angiographic evaluation demonstrated mild to moderate aortic regurgitation (AR) in one
(3.7%) patient, wereas none or trivial AR were observed in 26 (96.3%) patients. Major
adverse cardiovascular events within 30 days (according to VARC) occurred in 22.2%
(death 14.8%, stroke 3.7%, pacemaker implantation for new onset conduction distur-
bances 3.7%). Survival at 3 month was 81.5% (n24). Echocardiographic evaluation 3
month after implantation (n18/23) demonstrated moderate AR in 1 (3.7%) patient and
none or trivial AR in 11 (40%) and 6 (22.2%) patients, respectively. The mean
transvalvular gradient at 1 and 3 month after implantation was 17.910.5mmHg and
16.810.8mmHg, respectively.
Conclusions: The JenaValve™ is a safe and effective for transapical TAVI of severe AS.
Early echocardiographic data suggest valve function with a very low rate of significant
paravalvular regurgitation, however, a higher mean transvalvular gradient compared to
other TAVI devices.
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Background: Few data exists comparing transfemoral TAVI with Medtronic Cor-
eValve® (MCV) (Medtronic, Minneapolis, Minnesota) vs. Edwards SAPIEN™/SAPIEN
XT™ (ESV) (Edwards Lifesciences, Irvine, California) for severe aortic stenosis.
Methods: The prospective TAVI databases of 4 experienced centers in Europe were pooled
and analyzed comparing transfemoral MCV vs. ESV. Due to differences in baseline clinical
characteristics, a propensity score matching was performed. Study objectives were Valve
Academic Research Consortium (VARC) outcomes at 30 days and one year.
Results: In total, 793 patients were included: 453 (57.1%) treated with MCV and 340
(42.9%) with ESV. After propensity matching 252 patients were identified in each group.
In the matched cohort, at 30 days, there were no differences in all-cause mortality (MCV
8.7% vs. ESV 6.0%; Odds Ratio [OR] 1.511; 95% Confidence Interval [CI] 0.765-0.986;
p0.235), cardiac mortality (7.5% vs. 6.0%; OR 1.288; 95% CI 0.639-2.596; p0.478),
myocardial infarction (0.4% vs. 0.4%; OR 1.000; 95% CI 0.062-16.076; p1.000) or
device success (95.2% vs. 96.0%; OR 0.826; 95% CI 0.350-1.949; p0.663). Of note, a
trend toward more strokes was observed with MCV (3.6% vs. 1.2%; OR 3.074; 95% CI
0.822-11.491; p0.095). Conversely, there was an advantage of the MCV group in major
vascular complications (8.3% vs. 14.3%; OR 0.545; 95% CI 0.309-0.964; p0.037), but
not in life-threatening bleeding (12.3% vs. 12.3%; OR 1.000; 95% 0.588-1.702;
p1.000). Indeed, there was less need for PPM in the ESV group (22.6% vs. 6.8%; OR
4.024; 95% CI 2.266-7.143; p0.001). At one year, there was no difference in all-cause
(16.3% vs. 13.9%; OR 1.085; 95% CI 0.592-1.987; p0.518) or cardiac mortality (8.7%
vs. 7.9%; OR 1.085; 95% CI 0.592-1.987; p0.783).
Conclusions: No differences between the 2 commercially available transfemoral TAVI
devices were observed in VARC outcomes at 30 days and one year except for major
vascular complications with ESV and need for PPM with MCV. A trend for less major
strokes was observed with ESV. These results need to be confirmed in a randomized trial.
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Background: To assess 30-day outcomes following transcatheter aortic valve implan-
tation (TAVI) according to the STS score, logistic EuroSCORE and the new logistic
EuroSCORE II.
Methods: All consecutive patients treated in our center by TAVI from November 2007
to May 2011, utilizing both commercially available valves, were analyzed. Patients were
grouped by low-, intermediate- and high-risk (STS 3%, 3-8%, 8%; logistic Euro-
SCORE 10%, 10-20%, 20%; logistic EuroSCORE II 5%, 5-10%, 10%; respec-
tively). Study endpoints were reported according to the Valve Academic Research
Consortium (VARC) definitions. The C-statistic was performed to calculate the discrim-
inative ability of the scores.
Results: A total of 417 patients were included: mean age was 79.57.5 years and 59.7%
underwent implantation of Edwards SAPIEN™/SAPIEN XT™. According to STS, there
were 17.7% patients in the low-, 49.2% in the intermediate- and 33.1% in the high-risk
category. According to logistic EuroSCORE, there were 20.6% patients in the low-,
31.9% in the intermediate- and 47.5% in the high-risk category. According to logistic
EuroSCORE II, there were 54.2% patients in the low-, 28.1% in the intermediate- and
17.7% in the high-risk category. Thirty-day mortality was 4.7% overall with no
differences according to risk stratification: according to STS from low to high risk
respectively 4.3% vs. 3.5% vs. 6.7% (p0.392), logistic EuroSCORE 3.7%- vs. 2.3% -
vs. 6.7% (p0.167) and logistic EuroSCORE II 3.2% vs. 6.2% vs. 6.8% (p0.307). The
C statistic for 30 day mortality for STS, logistic EuroSCORE, and logistic EuroSCORE
II were respectively 0.60, 0.66 and 0.62. All high-risk groups developed more acute
kidney injury stage 3 ( in high-risk STS 16.8%, logistic EuroSCORE 14.8% and logistic
EuroSCORE II 17.6%) and stroke was more frequent in the high-risk logistic Euro-
SCORE II group (0% vs. 0.9% vs. 5.4%; p0.001).
Conclusions: None of the available surgical risk scores were predictors of 30-day
mortality following TAVI. Moreover, the C statistics showed poor discriminative ability
of the scores for 30 day mortality. New scores are needed to help risk stratify TAVI
patients.
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Background: Trancatheter aortic valve implantation (TAVI) is an emerging treatment
option for inoperable or high risk patients. After the procedure, most of patients show
significant improvement of left ventricular function. However, the recovery of left
ventricle is not immediately observed to all patients while to some others, it is temporarily
deteriorated. Furthermore, some patients may elevate the levels of CRP and white blood
cells (WBC) after TAVI. Elevated CRP has been associated with reduced left ventricular
function. Therefore, we hypothesized that inflammatory parameters may influence left
ventricular recovery after TAVI.
Methods: Data from consecutive patients who underwent TAVI were evaluated from an
existed database. Blood samples were obtained before TAVI, 3 hours and daily for 5 days
after the procedure. CRP as well as WBC were recorded. In addition, transthoracic
echocardiogram was performed and obtained before TAVI and daily for 5 days after the
procedure. Patients were separated into three groups according to left ventricle improve-
ment (improved, unaffected, declined).
Results: Overall, data from 76 patients (80.375.36 years, 33 males (48.8%), AVA:
0.630.15 cm2) were analyzed. Out of them, in 29 patients (39.7%) LVEF improved, in
11 patients (15.1%) it declined and in 33 patients (45.2%) it remained unaffected. We
performed ANNOVA test among three groups and we found significant differences
between groups for CRPmax (p0.01) and WBC1st day after (p0.01). In particular,
post-hoc analysis showed higher levels of CRPmax (70.249.28 vs. 12022.36, p0.01)
and WBC1st day after (163334685 vs. 117483512, p0.01) in patients with declined
LVEF comparing to those with unaffected LVEF respectively. Similarly, post-hoc
analysis recorded greater value for CRPmax (12022.36 vs. 61.9936.9, p0.01) and
WBC1st day after (165284890 vs. 108002687, p0.01) in patients with declined
LVEF when compared with those with improved LVEF.
Conclusions: In conclusion, inflammation as detected by simple indices such WBC and
CRP may be associated with left ventricular function after TAVI.
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